
Another First-Line Combo Succeeds in Advanced RCC
- Wellness
- Admin COUPONS
- September 20, 2020
(MedPage Today) — Advanced or metastatic kidney cancer patients treated with the PD-1 checkpoint inhibitor nivolumab (Opdivo) plus cabozantinib (Cabometyx) lived twice as long without disease progression compared to patients receiving an older…
%%item_READ_MORE…_button%%